Ribonexus is a biotech specializing in the development of new therapies to combat cancer disease.
Ribonexus has raised $1.5M in total funding. The most recent round was Debt Financing. The last funding was announced in April 2022.
Ribonexus's investors include Bpifrance, AdBio partners, Pierre Fabre, Crédit Mutuel Innovation.
Ribonexus is headquartered in Paris, France.
Ribonexus is a biotech specializing in the development of new therapies to combat cancer disease.
Ribonexus is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ribonexus — Funding & Investors." VCBacked, April 12, 2022, https://www.vcbacked.co/company/ribonexus. Accessed September 29, 2026.
VCBacked. (2022). Ribonexus — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/ribonexus
{{cite web |title=Ribonexus — Funding & Investors |url=https://www.vcbacked.co/company/ribonexus |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated